We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Phase III trial data shows more than half of patients with moderate to severe Crohn’s disease treated with risankizumab (Skyrizi®) 360mg achieved clinical remission in a year.